Valuation: VolitionRx Limited

Market Cap 3.29M 2.94M 2.74M 2.49M 4.69M 317M 4.73M 33.09M 12.87M 162M 12.37M 12.1M 521M P/E 2026 *
-0.12x
P/E 2027 * -0.23x
Enterprise Value 3.29M 2.94M 2.74M 2.49M 4.69M 317M 4.73M 33.09M 12.87M 162M 12.37M 12.1M 521M EV / Sales 2026 *
1.21x
EV / Sales 2027 * 0.36x
Free-Float
94.07%
Yield 2026 *
-
Yield 2027 * -
1 day-1.28%
1 week-8.26%
Current month-10.08%
1 month-33.64%
3 months-83.43%
6 months-93.24%
Current year-95.46%
1 week 0.23
Extreme 0.23
0.26
1 month 0.23
Extreme 0.23
0.36
Current year 0.23
Extreme 0.23
7.73
1 year 0.23
Extreme 0.23
13.4
3 years 0.23
Extreme 0.23
24.6
5 years 0.23
Extreme 0.23
82.8
10 years 0.23
Extreme 0.23
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Director/Board Member 55 06/10/2011
Director/Board Member 77 06/10/2011
Director/Board Member 64 09/10/2019
Date Insider Type Main position Quantity % Market Cap. Importance
9/28/26 A Tax

Executive/Senior Manager

-284 0.0021%
9/28/26 A Tax

Chief Operating Officer

-608 0.0045% -
3/17/26 A
Concord International, Inc.
OtherCompany 0 0% -
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%-8.26%-98.21%-98.34% 3.29M
+4.16%+3.42%+49.37%+94.17% 74.31B
+1.85%-2.45%+21.74%+76.99% 56.95B
+2.42%+0.99%+5.85%+37.48% 48.3B
+0.50%+2.94%+344.62%+722.17% 44.51B
+3.05%-1.80%+28.78%+34.51% 43.8B
+1.00%-1.46%+5.17%+111.90% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.51%+8.22%+37.86%+32.49% 28.97B
+0.76%-1.45%-7.44%-11.12% 24.53B
Average +1.73%-0.96%+39.70%+105.91% 39.36B
Weighted average by Cap. +2.24%-0.46%+58.96%+137.08%

Financials

2026 *2027 *
Net sales 2.72M 2.43M 2.26M 2.06M 3.88M 262M 3.91M 27.35M 10.64M 134M 10.22M 10M 430M 9.27M 8.27M 7.71M 7.01M 13.21M 893M 13.31M 93.14M 36.24M 456M 34.82M 34.07M 1.47B
Net income -22.25M -19.85M -18.49M -16.83M -31.69M -2.14B -31.93M -223M -86.94M -1.09B -83.53M -81.73M -3.52B -18.42M -16.43M -15.31M -13.93M -26.24M -1.77B -26.43M -185M -71.97M -905M -69.14M -67.65M -2.91B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a company focused on advancing the science of epigenetics. The Company is focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its products are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
57
Date Price Change Volume
05/10/26 $0.2320 -1.28% 716,926
02/10/26 $0.2350 +0.13% 1,381,586
01/10/26 $0.2347 -9.03% 8,137,816
30/09/26 $0.2580 +0.74% 1,444,917
29/09/26 $0.2561 +1.27% 2,105,656
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2320USD
Average target price
13.62USD
Spread / Average Target
+5,771.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock